These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
42. Management of diabetic retinopathy: a systematic review. Mohamed Q; Gillies MC; Wong TY JAMA; 2007 Aug; 298(8):902-16. PubMed ID: 17712074 [TBL] [Abstract][Full Text] [Related]
43. Long-term outcomes of treat-and-extend ranibizumab with and without navigated laser for diabetic macular oedema: TREX-DME 3-year results. Payne JF; Wykoff CC; Clark WL; Bruce BB; Boyer DS; Brown DM; Br J Ophthalmol; 2021 Feb; 105(2):253-257. PubMed ID: 32303499 [TBL] [Abstract][Full Text] [Related]
44. Antiangiogenic therapy with anti-vascular endothelial growth factor modalities for diabetic macular oedema. Parravano M; Menchini F; Virgili G Cochrane Database Syst Rev; 2009 Oct; (4):CD007419. PubMed ID: 19821414 [TBL] [Abstract][Full Text] [Related]
45. Racial disparities in the screening and treatment of diabetic retinopathy. Coney JM; Scott AW J Natl Med Assoc; 2022 Apr; 114(2):171-181. PubMed ID: 35105457 [TBL] [Abstract][Full Text] [Related]
46. [Guidelines of clinical practice of the SERV (Spanish Retina and Vitreous Society): management of ocular complications of diabetes. Diabetic retinopathy and macular oedema]. Pareja-Ríos A; Serrano-García MA; Marrero-Saavedra MD; Abraldes-López VM; Reyes-Rodríguez MA; Cabrera-López F; López-Gálvez M; Cardona-Guerra P; Abreu-Reyes P; Quijada-Fumero E; Coronado-Toural A; Gutiérrez-Sánchez E; Gil-Hernández MA; Valls-Quintana P; Marín-Olmos F; Navarro-Alemany R Arch Soc Esp Oftalmol; 2009 Sep; 84(9):429-50. PubMed ID: 19809923 [TBL] [Abstract][Full Text] [Related]
47. Biologic Therapy and Treatment Options in Diabetic Retinopathy with Diabetic Macular Edema. Nissen TPH; Vorum H; Aasbjerg K Curr Drug Saf; 2021; 16(1):17-31. PubMed ID: 32881673 [TBL] [Abstract][Full Text] [Related]
48. Pharmacological approach to diabetic macular edema. Bandello F; Casalino G; Loewenstein A; Goldstein M; Pelayes D; Battaglia Parodi M Ophthalmic Res; 2014; 51(2):88-95. PubMed ID: 24356667 [TBL] [Abstract][Full Text] [Related]
49. Optimal current and future treatments for diabetic macular oedema. Blumenkranz MS Eye (Lond); 2010 Mar; 24(3):428-34. PubMed ID: 20075969 [TBL] [Abstract][Full Text] [Related]
50. Serous retinal detachment after panretinal photocoagulation for proliferative diabetic retinopathy: a case report. Schatz P; Aldayel A; Taskintuna I; Abdelkader E; Mura M J Med Case Rep; 2017 Sep; 11(1):265. PubMed ID: 28923115 [TBL] [Abstract][Full Text] [Related]
51. Treatment options for diffuse diabetic macular edema. Bandello F; Iacono P; Battaglia Parodi M Eur J Ophthalmol; 2011; 21 Suppl 6():S45-50. PubMed ID: 23264328 [TBL] [Abstract][Full Text] [Related]
52. Long-term effect of intravitreal bevacizumab (avastin) in patients with chronic diffuse diabetic macular edema. Kook D; Wolf A; Kreutzer T; Neubauer A; Strauss R; Ulbig M; Kampik A; Haritoglou C Retina; 2008 Oct; 28(8):1053-60. PubMed ID: 18779710 [TBL] [Abstract][Full Text] [Related]
53. Impact of baseline Diabetic Retinopathy Severity Scale scores on visual outcomes in the VIVID-DME and VISTA-DME studies. Staurenghi G; Feltgen N; Arnold JJ; Katz TA; Metzig C; Lu C; Holz FG; Br J Ophthalmol; 2018 Jul; 102(7):954-958. PubMed ID: 29051325 [TBL] [Abstract][Full Text] [Related]
54. Cost-effectiveness of Intravitreous Ranibizumab Compared With Panretinal Photocoagulation for Proliferative Diabetic Retinopathy: Secondary Analysis From a Diabetic Retinopathy Clinical Research Network Randomized Clinical Trial. Hutton DW; Stein JD; Bressler NM; Jampol LM; Browning D; Glassman AR; JAMA Ophthalmol; 2017 Jun; 135(6):576-584. PubMed ID: 28492920 [TBL] [Abstract][Full Text] [Related]
55. Five-Year Outcomes of Panretinal Photocoagulation vs Intravitreous Ranibizumab for Proliferative Diabetic Retinopathy: A Randomized Clinical Trial. Gross JG; Glassman AR; Liu D; Sun JK; Antoszyk AN; Baker CW; Bressler NM; Elman MJ; Ferris FL; Gardner TW; Jampol LM; Martin DF; Melia M; Stockdale CR; Beck RW; JAMA Ophthalmol; 2018 Oct; 136(10):1138-1148. PubMed ID: 30043039 [TBL] [Abstract][Full Text] [Related]
56. Diabetic Macular Edema: Traditional and Novel Treatment. Tomić M; Vrabec R; Poljičanin T; Ljubić S; Duvnjak L Acta Clin Croat; 2017 Mar; 56(1):124-132. PubMed ID: 29120156 [TBL] [Abstract][Full Text] [Related]
57. Repeated intravitreous ranibizumab injections for diabetic macular edema and the risk of sustained elevation of intraocular pressure or the need for ocular hypotensive treatment. Bressler SB; Almukhtar T; Bhorade A; Bressler NM; Glassman AR; Huang SS; Jampol LM; Kim JE; Melia M; JAMA Ophthalmol; 2015 May; 133(5):589-97. PubMed ID: 25719991 [TBL] [Abstract][Full Text] [Related]
58. [Combination therapy in patients with concomitant macular edema and proliferative diabetic retinopathy]. Khomyakova EN; Ryabtseva AA; Sergushev SG; Grishina EE Vestn Oftalmol; 2019; 135(6):67-72. PubMed ID: 32015310 [TBL] [Abstract][Full Text] [Related]
59. Diabetic macular edema: Evidence-based management. Browning DJ; Stewart MW; Lee C Indian J Ophthalmol; 2018 Dec; 66(12):1736-1750. PubMed ID: 30451174 [TBL] [Abstract][Full Text] [Related]
60. Intravitreal bevacizumab injection alone or combined with macular photocoagulation compared to macular photocoagulation as primary treatment of diabetic macular edema. Javanović S; Canadanović V; Sabo A; Grgić Z; Mitrović M; Rakić D Vojnosanit Pregl; 2015 Oct; 72(10):876-82. PubMed ID: 26665553 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]